Extraction And Isolation Of Chemical Compound From Tabernaemontana Divaricata (L.) R.Br. Ex Roem. & Schult. Leaves With Potential 

Anti-Neuraminidase Activity by Zalaludin, Ayunni Salihah
EXTRACTION AND ISOLATION OF CHEMICAL 
COMPOUND FROM TABERNAEMONTANA 
DIVARICATA (L.) R.BR. EX ROEM. & SCHULT. 
LEAVES WITH POTENTIAL  
ANTI-NEURAMINIDASE ACTIVITY 
 
 
 
 
 
 
 
 
AYUNNI SALIHAH BINTI ZALALUDIN 
 
 
 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA  
2015 
EXTRACTION AND ISOLATION OF CHEMICAL 
COMPOUND FROM TABERNAEMONTANA 
DIVARICATA (L.) R.BR. EX ROEM. & SCHULT. 
LEAVES WITH POTENTIAL  
ANTI-NEURAMINIDASE ACTIVITY 
 
 
 
 
 
BY 
 
 
 
 
 
AYUNNI SALIHAH BINTI ZALALUDIN 
 
 
 
 
 
Thesis submitted in fulfillment of the requirements for the degree of  
Master of Science  
 
SEPTEMBER 2015 
ii 
 
ACKNOWLEDGEMENTS 
 
Alhamdulillah…Thank you Allah for giving me courage and strength to complete 
my study. I owe my deepest gratitude to my supervisor, Prof. Dr. Habibah A. Wahab 
for her continuous supports, advises and guidance over the years. I would like to 
thank my co-supervisor, Dr. Maizan Mohamed for her encouragement and opinion in 
this study. 
 
I would also like to express my sincere appreciation to Nur Kusaira for her help and 
guidance in conducting bioassay analysis. I would never forget the help I got from 
Maywan, Yusuf, Adila and all PhDS lab members while doing computational 
docking study. Thank you so much for your time and guidance. Special thanks to Dr. 
Che Puteh Osman for helping and guiding me in elucidating the compound structure. 
 
Million thanks to Azimah, Norizamimie, Ilyana, Anuar, Faisalina and Zuraidah for 
their valuable helps, supports and continuous motivation throughout my study. I am 
pleased to thank everyone who involved and helped directly and indirectly along this 
memorable journey of mine. 
 
Special dedication goes to my family members for their endless love, support, 
understanding and encouragement. To my dearest Ummi and Abah, thank you so 
much for your prayers and blessings. 
 
 
 
 
iii 
 
TABLE OF CONTENTS 
 Page 
ACKNOWLEDGEMENTS  ………………………………………………... ii 
TABLE OF CONTENTS ..………………………………………………….. iii 
LIST OF TABLES  …………………………………………...……………... vii 
LIST OF FIGURES ………………………………...……………………….. viii 
LIST OF SYMBOLS AND ABBREVIATION ……...…………………….. xiii 
LIST OF APPENDICES ……………………………………..….………….. xvi 
LIST OF PUBLICATION …………………………………………………... xvii 
ABSTRAK ……..………………………………………………….…………. xviii 
ABSTRACT ...................................................................................................... xx 
  
CHAPTER 1: INTRODUCTION  
1.1       The Influenza Virus ............................................................................... 1 
1.2 Influenza Pandemic …………………..………….……………………. 4 
1.3 Influenza A Virus Structure ……………………...…………………… 6 
1.4 Haemagglutinin (HA) ..…………………………..………….………... 7 
1.5 Neuraminidase Enzyme (NA) …………………………..……….……. 8 
1.6 Neuraminidase Active Sites ……………………………..……….….... 10 
1.7 Neuraminidase Inhibitor and The Development of Antivirals ...…….... 13 
1.7.1  2-deoxy-2,3-dehydro-N-acetylneuraminic acid 
(Neu5Ac2en/DANA) and  2-deoxy-2,3-dehydro-N-
trifluoroacetylneuraminic acid (FANA)  ……………………….. 14 
 
1.7.2 Adamantane Derivatives …………………….……………..…… 
 
15 
1.7.3 Oseltamivir and Zanamivir ……………………………..………. 16 
iv 
 
1.8       Anti-Influenza from Natural Product …………………………………. 18 
            1.8.1 Tabernaemontana divaricata (L.) R.Br. ex Roem. & Schult. ….. 20 
            1.8.2 Traditional Use of Tabernaemontana divaricata Plant Parts …... 22 
            1.8.3 Recent Study on Tabernaemontana divaricata Plant ………....... 23 
            1.8.4 Alkaloid Chemical Constituents from Tabernaemontana 
divaricata ……………………………………………………….. 
 
24 
            1.8.5 Alkaloids ...…………………………………………………….... 27 
            1.8.6 Alkaloids with Anti-Influenza Activity ……………………….... 29 
1.9       Computational Docking …………………………………………...….. 30 
1.10     Objectives of Study ................................................................................ 32 
 
CHAPTER 2: MATERIALS AND METHODS  
2.1       Research Activities …………………………………………………….. 34 
2.2       Extraction and Isolation of Chemical Constituent from   
            Tabernaemontana divaricata Leaves ……………….…………………. 
 
36 
2.2.1 Plant Material ……………………………………………...…… 36 
2.2.2 Chemicals ……………………………………..……………….. 36 
2.2.3  Instruments …....……………………………………..………… 37 
2.2.4 Experimental ..…………………………….………..……........... 38 
2.2.4[a] Extraction of Crude Sample …………………..……..... 38 
2.2.4[b] Fractionation and Isolation of Compound ………...….. 39 
2.2.4 [c] Compound 1 ……………………………….…..……... 41 
2.3      Neuraminidase Inhibition Assay ..………………………...………….…. 43 
2.3.1 Chemicals…………………………………………….................. 43 
2.3.2 Methods………………………………………….…………….... 44 
            2.3.2 [a] Preparation of Stock Solutions …………………....….. 44 
v 
 
            2.3.2 [b] Preparation of Working Solutions …….…………...…. 44 
                        2.3.2 [c] Neuraminidase Inhibition Assay …………………....... 46 
                        2.3.2[d] Data Analysis …………………………………….....… 48 
2.4       Molecular Docking ……………………………………………...…..…. 49 
            2.4.1 Materials ………………………………………………..….…..…. 49 
            2.4.2 Methods ..……………………………………………….…..…..... 49 
                        2.4.2 [a] Preparation of Macromolecule ……………….…....…. 49 
                        2.4.2 [b] Preparation of Ligands ……………………….………. 50 
                        2.4.2 [c] Grid Map Calculation ………………………….…....... 50 
                        2.4.2 [d] Docking Simulation …………………………….…...... 51 
                        2.4.2 [e] Docking Analysis ………………………………...…... 51 
  
CHAPTER 3: RESULTS AND DISCUSSION  
3.1 Extraction of Tabernaemontana divaricata Leaves ……………...…….. 52 
3.2 Analysis of the Isolated Compound 1 …………………………...……... 54 
            3.2.1 Characterisation of Compound 1 …………………………..…...... 54 
            3.2.2 Infrared Spectroscopy of Compound 1 ……………………..…..... 57 
            3.2.3 Specific Rotation of Compound 1 …………………………..……. 58 
            3.2.4 
1
H-NMR, COSY and HMBC Analyses of Compound 1 ……........ 59 
            3.2.5 
13
C-NMR, DEPT and HMQC Analyses of Compound 1 .……...... 65 
            3.2.6 Identification of Compound 1 ………………………………...….. 69 
3.3       Neuraminidase Enzyme Assay (MUNANA Assay) …………….……... 73 
3.4       Molecular Docking ……………………………………………..….…... 99 
            3.4.1 Control Docking ……………………………………………...…... 99 
vi 
 
            3.4.2 Automated Docking Comparison between Oseltamivir, DANA, 
Voaphylline and Ervayunine with 3TI6 Macromolecule ………… 104 
                        3.4.2[a] RMSD Value and Binding Energy ……………………. 106 
                        3.4.2[b] Hydrogen Bond Interaction …………………...……..... 109 
                        3.4.2[c] Cation-π Bond Interaction …………………….…..…... 115 
                        3.4.2[d] Neuraminidase Enzyme Assay …………………...…… 118 
  
CHAPTER 4: CONCLUSION AND RECOMMENDATIONS  
4.1        Conclusion …………………………………………………………...... 120 
4.2        Recommended Future Works ……………………………..………….... 123 
REFERENCES ……………………………………………………………...… 125 
APPENDICES   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
LIST OF TABLES  
Table Titles Page 
1.1 Synonyms of Tabernaemontana divaricata (L.) R.Br. ex Roem. & 
Schult. obtained from The Plant List website (2013) 
 
21 
1.2 Alkaloid  chemical constituents that have been isolated from 
Tabernaemontana divaricata plant 
 
25 
1.3 Example of determination of alkaloid nomenclature based on plant 
bearing the compound, physiological activity or also from the 
name of the discoverer of the compounds (Hesse 1981) 
 
29 
2.1 List of chemicals used in extraction and isolation of chemical 
compound from Tabernaemontana divaricata leaves 
 
36 
2.2 Solvent systems used in gravity column chromatography 
 
40 
2.3 List of mobile phase systems for TLC analysis of Compound 1 
 
41 
2.4 List of chemicals used in neuraminidase inhibition assay 
 
43 
3.1 Weight and percent yield of IFNM CF1–IFNM CF14 
 
53 
3.2 The chemical shift of Compound 1 
 
64 
3.3 
1
H and 
13
C data comparison between voaphylline and ervayunine 
 
70 
3.4 Physical comparison between voaphylline and ervayunine 
 
71 
3.5 Summary of hydrogen bond interactions between oseltamivir with 
amino acid residues of 3TI6 receptor 
 
103 
3.6 Comparison between control docking of oseltamivir and docking 
of voaphylline, ervayunine and DANA with 3TI6 macromolecule 
 
105 
3.7 Summary of hydrogen bond interactions between control docking 
of oseltamivir and docking of voaphylline, ervayunine and DANA 
with 3TI6 macromolecule 
 
112 
3.8 Summary of cation-π bond interactions between voaphylline and 
ervayunine with arginine amino acid residues of 3TI6 receptor
  117 
 
 
viii 
 
LIST OF FIGURES 
Figure Titles Page 
1.1 Influenza A virus structure (Davidson 2005) 6 
1.2 Illustration of five neuraminidase active sites (S1-S5) with 
Neu5Ac2en inhibitor (Stoll et al. 2003) 
 
11 
1.3 Illustration of oseltamivir bounds to the wild type strain of 2009-
H1N1 influenza neuraminidase. This modelled structure was 
adapted and modified from Rungrotmongkol et al. (2010). 
 
12 
1.4 Mechanism of action of neuraminidase inhibitors.  
A: Replication and release of virus to new host cells continues as 
neuraminidase enzyme cleaves the receptor containing sialic acid 
that binds with haemagglutinin  
B: Viral replication discontinued as neuraminidase inhibitor binds 
to the active site (Moscona 2005) 
 
13 
1.5 Molecular structures of 2-deoxy-2,3-dehydro-N-acetylneuraminic 
acid (DANA) and Neu5Ac2en 2-deoxy-2,3-dehydro-N-
trifluoroacetylneuraminic acid (FANA) (Clercq 2006) 
 
14 
1.6 Molecular structures of M2 channel inhibitors; rimantadine (left) 
and amantadine (right)  (Liu et al. 2010) 
 
15 
1.7 Molecular structures of neuraminidase inhibitors; zanamivir and 
oseltamivir (Liu et al. 2010) 
 
17 
1.8 Pictures of Tabernaemontana divaricata plant, taken from 
sampling site 
 
20 
1.9 Chemical structure of morphine, the first pure alkaloid isolated  
(Cordell 1981) 
 
28 
1.10 Illustration of grid box surrounding binding site of target protein 
(Morris et al. 2001) 
 
31 
2.1 Flow chart of research activities 
 
35 
2.2 Illustration of MUNANA assay plate design 47 
2.3 Reaction principle of microplate-based screening assay for 
neuraminidase inhibitors (Li et al. 2009) 
48 
ix 
 
3.1 Chemical structure of Compound 1 54 
3.2 TLC analyses of Compound 1, sprayed with Dragendorff reagent 55 
3.3 Mass spectrum of Compound 1 56 
3.4 IR spectrum of Compound 1 57 
3.5 1H-NMR spectrum of Compound 1 60 
3.6 HMBC spectrum of Compound 1 60 
3.7 HMBC correlation of Compound 1 61 
3.8 COSY spectrum of Compound 1 62 
3.9 1H-
1
H (COSY) correlation of Compound 1 62 
3.10 13C-NMR spectrum of Compound 1 66 
3.11 (a) DEPT 45 spectrum of Compound 1 66 
3.11 (b) DEPT 90 spectrum of Compound 1 67 
3.11 (c) DEPT 135 spectrum of Compound 1 67 
3.12 HMQC spectrum of Compound 1 68 
3.13 The complete carbon and proton assignments of Compound 1 69 
3.14 Comparison of voaphylline and ervayunine chemical structure 
 
72 
3.15 Inhibition activity (%) of DANA, methanol and alkaloid extracts 
of Tabernaemontana divaricata against Clostridium perfringens 
neuraminidase at 0.5-250 µg/mL sample concentrations 
 
75 
3.16 Inhibition activity (%) of DANA, methanol and alkaloid extracts 
of Tabernaemontana divaricata against H1N1 neuraminidase at 
0.5-250 µg/mL sample concentrations 
 
75 
3.17 Inhibition activity (%) of DANA, methanol and alkaloid extracts 
of Tabernaemontana divaricata against H5N1 neuraminidase at 
0.5-250 µg/mL sample concentrations 
 
76 
3.18 Bar graphs of inhibition activity (%) against Clostridium 
perfringens neuraminidase shown by a) DANA  b) methanol 
extract  c) alkaloid extract vs concentrations (0.5-250 µg/mL) of 
samples tested, compared relatively to the activity of positive 
78 
x 
 
control. The asterisks (*) indicate significant differences from 
positive control (one-way ANOVA (p<0.05) with Dunnett’s 
multiple comparison test). Values are expressed as means±SD 
 
3.19 Bar graphs of inhibition activity (%) against H1N1 neuraminidase 
shown by a) DANA  b) methanol extract  c) alkaloid extract vs 
concentrations (0.5-250 µg/mL) of samples tested, compared 
relatively to the activity of positive control. The asterisks (*) 
indicate significant differences from positive control (one-way 
ANOVA (p<0.05) with Dunnett’s multiple comparison test). 
Values are expressed as means±SD 
 
79 
3.20 Bar graphs of inhibition activity (%) against H5N1 neuraminidase 
shown by a) DANA  b) methanol extract  c) alkaloid extract vs 
concentrations (0.5-250 µg/mL) of samples tested, compared 
relatively to the activity of positive control. The asterisks (*) 
indicate significant differences from positive control (one-way 
ANOVA (p<0.05) with Dunnett’s multiple comparison test). 
Values are expressed as means±SD 
 
80 
3.21 Inhibition activity (%) of DANA and fractions (CF1-CF14) 
against Clostridium prefingens neuraminidase at 0.5-250 µg/mL 
sample concentrations 
 
81 
3.22 Inhibition activity (%) of DANA and fractions (CF1-CF14) 
against H1N1 neuraminidase at 0.5-250 µg/mL sample 
concentrations 
 
82 
3.23 Inhibition activity (%) of DANA and fractions (CF1-CF14) 
against H5N1 neuraminidase at 0.5-250 µg/mL sample 
concentrations 
 
82 
3.24 Bar graph of inhibition activity (%) against Clostridium 
perfringens neuraminidase of fractions (CF1-CF14) vs 
concentrations (0.5-250 µg/mL) of samples tested, compared 
relatively to the activity of positive control. The asterisks (*) 
indicated significant differences from positive control (one-way 
ANOVA (p<0.05) with Dunnett’s multiple comparison test). 
Values are expressed as means±SD 
 
84 
3.25 Bar graph of inhibition activity (%) against H1N1 neuraminidase 
of fractions (CF1-CF14) vs concentrations (0.5-250 µg/mL) of 
samples tested, compared relatively to the activity of positive 
control. The asterisks (*) indicate significant differences from 
87 
xi 
 
positive control (one-way ANOVA (p<0.05) with Dunnett’s 
multiple comparison test). Values are expressed as means±SD 
 
3.26 Bar graph of inhibition activity (%) against H5N1 neuraminidase 
of fractions (CF1-CF14) vs concentrations (0.5-250 µg/mL) of 
samples tested, compared relatively to the activity of positive 
control. The asterisks (*) indicate significant differences from 
positive control (one-way ANOVA (p<0.05) with Dunnett’s 
multiple comparison test). Values are expressed as means±SD 
 
90 
3.27(a) Inhibition activity (%) of DANA and voaphylline against 
Clostridium perfringens neuraminidase at 0.5-250 µg/mL sample 
concentrations 
 
95 
3.27(b) Bar graph of inhibition activity (%) against Clostridium 
perfringens neuraminidase of voaphylline vs concentrations (0.5-
250 µg/mL) of samples tested, compared relatively to the activity 
of positive control. The asterisks (*) indicate significant 
differences from positive control (one-way ANOVA (p<0.05) with 
Dunnett’s multiple comparison test). Values are expressed as 
means±SD 
 
95 
3.28(a) Inhibition activity (%) of DANA and voaphylline against H1N1 
neuraminidase at 0.5-250 µg/mL sample concentrations 
 
96 
3.28(b) Bar graph of inhibition activity (%) against H1N1 neuraminidase 
of voaphylline vs concentrations (0.5-250 µg/mL) of samples 
tested, compared relatively to the activity of positive control. The 
asterisks (*) indicate significant differences from positive control 
(one-way ANOVA (p<0.05) with Dunnett’s multiple comparison 
test). Values are expressed as means±SD 
 
96 
3.29(a) Inhibition activity (%) of DANA and voaphylline against H5N1 
neuraminidase at 0.5-250 µg/mL sample concentrations 
 
97 
3.29(b) Bar graph of inhibition activity (%) against H5N1 neuraminidase 
of voaphylline vs concentrations (0.5-250 µg/mL) of samples 
tested, compared relatively to the activity of positive control. The 
asterisks (*) indicate significant differences from positive control 
(one-way ANOVA (p<0.05) with Dunnett’s multiple comparison 
test). Values are expressed as means±SD 
 
 
97 
xii 
 
3.30 Superimposition between the docked conformation No. 14 
(yellow) and the crystal structure 3TI6 (green); RMSD=1.24 Å, 
estimated free energy of binding of -10.08 kcal/mol [O=red, 
N=purple, H=grey] 
100 
 
 
 
 
3.31 Superimposition between the docked conformation No. 15 (blue) 
and the crystal structure 3TI6 (green); RMSD=0.77 Å, estimated 
free energy of binding of -9.53 kcal/mol [O=red, N=purple, 
H=grey] 
 
101 
3.32 Docking conformation of oseltamivir (run No. 15) and its binding 
interaction with amino acid residues of 3TI6 receptor. Green 
dotted lines indicate the hydrogen bonds formed between the 
ligand-receptor complex [O=red, N=purple, H=grey] 
 
102 
3.33 Superimposition of 3TI6 (red) and 3B7E (blue) crystal structures, 
shown in ribbon representation with enlarged binding pocket area 
107 
 
 
3.34 Docking conformation of voaphylline and its binding interaction 
with amino acid residues of 3TI6 receptor. Green dotted lines 
indicate the hydrogen bonds formed between the ligand-receptor 
complex 
 
110 
3.35 Docking conformation of ervayunine and its binding interaction 
with amino acid residues of 3TI6 receptor. Green dotted lines 
indicate the hydrogen bonds formed between the ligand-receptor 
complex 
 
110 
3.36 Docking conformation of DANA and its binding interaction with 
amino acid residues of 3TI6 receptor. Green dotted lines indicate 
the hydrogen bonds formed between the ligand-receptor complex 
 
111 
3.37 Docking conformation of voaphylline and its cation-π bond 
interaction with amino acid residues of 3TI6 receptor. Orange 
lines indicate the cation-π bonds formed between the ligand-
receptor complex 
 
116 
3.38 Docking conformation of ervayunine and its cation-π bond 
interaction with amino acid residues of 3TI6 receptor. Yellow 
lines indicate the cation-π bonds formed between the ligand-
receptor complex 
 
116 
 
xiii 
 
LIST OF SYMBOLS AND ABBREVIATION 
ADT AutoDockTools 
Ala Alanine 
Arg Arginine 
Asn Asparagine 
Asp Aspartic acid 
ATR-FTIR Attenuated Total Reflectance - Fourier Transform Infrared  
c    Concentration 
C Carbon 
CaCl2 Calcium chloride 
CC Column Chromatography 
CF Combine Fraction 
CDCl3 Deuterated Chloroform 
cm centimetre 
CNS central nervous system 
COSY Heteronuclear Correlation Spectroscopy 
d Doublet 
dd Doublet of Doublet 
ddH2O deionised water 
DEPT Distortionless Enhancement by Polarization Transfer 
dm decimetre 
DMSO Dimethyl sulfoxide 
DSC Differential Scanning Calorimetry 
ECG electrocardiogram 
EtOH Ethanol 
F Fluorine 
FANA 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid 
FEB Free Energy of Binding 
g grams 
Glu Glutamic acid 
H Hydrogen 
HA haemagglutinin 
HMBC Heteronuclear Multiple-Bond Correlation 
xiv 
 
HMQC Heteronuclear Multiple Quantum Coherence 
Ile Isoleucine 
IPharm Malaysian Institute of Pharmaceuticals and Nutraceuticals 
IR Infrared 
kg kilogram 
L Litre 
LCMS QTOF Liquid Chromatography-Mass Spectrometry Quadrupole-Time-
of-Flight 
m multiplet 
M Molar 
mL millilitre 
M2 Matrix protein 
MeOH Methanol 
MES 2-(N-morpholino) ethanesulfonic acid 
MHz Megahertz  
MIC minimum inhibitory concentration 
mm millimetre 
mM millimolar 
m.p Melting Point 
MUNANA 2’2-(4-Methylumbelliferyl)-a-D-N-acetylneuraminic acid 
sodium salt hydrate 
m/z mass-to-charge-ratio 
N Nitrogen 
NA neuraminidase 
NADI Natural Product Discovery 
NAI Neuraminidase Inhibitor 
NaOH Sodium hydroxide 
Neu5Ac acetylneuraminic acid 
Neu5Ac2en/DANA 2-deoxy-2,3-dehydro-N-acetylneuraminic acid 
NMR Nuclear Magnetic Resonance 
O Oxygen 
PDB Protein Data Bank 
q quadruplet 
xv 
 
RMSD Root Mean Square Deviation 
RNA Ribonucleic acid 
s singlet 
sd Singlet of Doublet 
Ser Serine 
SA sialic acid 
syn synonym 
t Triplet 
T Temperature 
TLC thin layer chromatography 
Trp Tryptophan 
Tyr Tyrosine 
U Unit 
USM Universiti Sains Malaysia 
UV Ultraviolet 
3-D 3-Dimensional 
Å Angstrom  
o
C Degree Celsius 
%  percentage 
μL microlitre 
α Specific rotation 
λ Wavelength 
w/v Weight per volume 
l Tube length 
π Pi 
 
 
 
 
 
 
 
xvi 
 
LIST OF APPENDICES 
Appendix Titles 
A Result of virtual screening (docking) of compounds from NADI 
database with H1N1 neuraminidase crystal structure (code 3B7E) 
 
B IR spectrum of voaphylline 
C Specific rotation of voaphylline (C1) 
D 
1
H-NMR spectrum of voaphylline 
E HMBC spectrum of voaphylline 
F COSY spectrum of voaphylline 
G 
13
C-NMR spectrum of voaphylline 
H DEPT NMR spectrum of voaphylline 
I HMQC spectrum of voaphylline 
J Clustering histogram for control docking of oseltamivir with 3TI6 
receptor 
 
K RMSD table for control docking of oseltamivir with 3TI6 receptor 
L Clustering histogram for docking of voaphylline with 3TI6 receptor 
M Clustering histogram for docking of ervayunine with 3TI6 receptor 
N 
 
Clustering histogram for docking of DANA with 3TI6 receptor 
 
 
 
 
 
 
 
 
xvii 
 
LIST OF PUBLICATION 
 
1. IKRAM, N. K. K., DURRANT J. D., MUCHTARIDI, M., ZALALUDIN, A. 
S., PURWITASARI, N., MOHAMED, N., RAHIM A. S., LAM, C. K., 
NORMI, Y. M., RAHMAN, N. A., AMARO, R. E. & WAHAB, H. A. 
(2015). A Virtual Screening Approach for Identifying Plants with Anti H5N1 
Neuraminidase Activity. Journal of Chemical Information and Modeling, 
55(2), 308-316. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xviii 
 
PENGEKSTRAKAN DAN PENGASINGAN SEBATIAN KIMIA DARI DAUN  
TABERNAEMONTANA DIVARICATA (L.) R.BR. EX ROEM. & SCHULT. 
YANG BERPOTENSI SEBAGAI AKTIVITI ANTI-NEURAMINIDASE 
 
 
ABSTRAK 
 
Virus influenza telah dikenal pasti sebagai salah satu jangkitan paling lazim 
yang menyerang sistem pernafasan manusia. Virus ini boleh menyebabkan penyakit 
serius yang boleh membawa kepada peningkatan kadar penyakit dan kematian.  
Neuraminidase (NA) yang turut dikenali sebagai sialidase ialah protein tetramer yang 
memainkan peranan penting dalam kehidupan virus influenza. Ini termasuk 
membantu pembebasan virus ke sel-sel yang berhampiran. Oleh itu, NA telah dikenal 
pasti sebagai sasaran untuk membangunkan strategi terapi bagi melawan jangkitan 
virus. Kajian ini menumpukan kepada pengekstrakan, fraksinasi dan pengasingan 
sebatian kimia alkaloid yang berpotensi sebagai aktiviti anti-neuraminidase dari 
Tabernaemontana divaricata yang telah dikenal pasti melalui penyaringan maya dari 
pangkalan data NADI diikuti dengan penilaian-penilaian in vitro dan in silico ke atas 
sebatian yang telah diasingkan bersama-sama dengan drug standard (DANA). 
Pengasingan sebatian dikenali sebagai voafilin (0.059 g/kg) telah diperoleh daripada 
salah satu daripada empat belas fraksi yang telah dikumpulkan melalui pengasingan 
turus kromatografi. Penilaian in vitro bagi DANA, ekstrak-ekstrak metanol dan 
alkaloid, fraksi-fraksi dan sebatian voafilin telah dicapai melalui asai MUNANA 
diikuti dengan penilaian in silico bagi DANA, voafilin dan enantiomernya 
(ervayunin) melalui kajian pendokan molekul yang telah dijalankan menggunakan 
perisian AutoDock 4.2. Asai perencatan neuraminidase (asai MUNANA) bagi 
xix 
 
DANA telah menunjukkan IC50 27.76 ± 0.14, 4.25 ± 0.07 dan 12.05 ± 0.09 µg/mL 
terhadap neuraminidase dari Clostridium perfringens, H1N1 dan H5N1. Ekstrak-
ekstrak metanol dan alkaloid, fraksi-fraksi dan sebatian yang diasingkan telah 
menunjukkan kesan perencatan yang ketara (p<0.05) berbanding kawalan positif di 
dalam asai perencatan neuraminidase terhadap ketiga-tiga jenis enzim 
neuraminidase. Kajian pendokan molekul bagi voafilin yang telah dijalankan melalui 
perisian AutoDock 4.2 telah menunjukkan bahawa voafilin, ervayunin dan DANA 
mempunyai tenaga pengikatan yang rendah iaitu masing-masing -7.31, -5.52 dan       
-6.29 kcal/mol dengan reseptor neuraminidase H1N1 (kod PDB: 3TI6) dengan 
penglibatan beberapa interaksi pengikatan telah diramalkan. Penyaringan in silico 
bagi sebatian-sebatian telah menunjukkan bahawa ramalan tumbuh-tumbuhan yang 
mengandungi sebatian kimia yang menarik bagi penyakit tertentu boleh dicapai 
melalui teknik pengkomputeran dengan pengesahan bagi aktiviti sebatian yang 
dijangka adalah tertakluk kepada penilaian uji kaji melalui asai in vitro. 
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EXTRACTION AND ISOLATION OF CHEMICAL COMPOUND FROM  
TABERNAEMONTANA DIVARICATA (L.) R.BR. EX ROEM. & SCHULT. 
LEAVES WITH POTENTIAL ANTI-NEURAMINIDASE ACTIVITY 
  
 
ABSTRACT 
 
Influenza virus was identified as one of the most common pathogens that 
infect human respiratory system. The infection may cause serious illness which could 
lead to high morbidity and mortality rate. Neuraminidase (NA), also known as 
sialidase is a tetramer protein which plays important roles in the life of influenza 
virus. This includes facilitating the release of the virus to other neighbouring cells. 
Thus NA has been identified as the target to develop therapeutic strategies against 
the viral infection. This study is focused on the extraction, fractionation and isolation 
of alkaloid chemical constituent with potential anti-neuraminidase activity from 
Tabernaemontana divaricata, identified by virtual screening from NADI database 
followed by in vitro and in silico evaluations of the isolated compound along with 
standard drug (DANA). Isolation of compound known as voaphylline (0.059 g/kg) 
was obtained from one of the fourteen fractions collected via column 
chromatography separation. In vitro evaluations of DANA, methanol and alkaloid 
extracts, fractions and voaphylline compound were achieved via MUNANA assay 
followed by in silico evaluations of DANA, voaphylline and its enantiomer 
(ervayunine) via molecular docking study performed using AutoDock 4.2 software. 
Neuraminidase inhibition assay (MUNANA assay) of DANA showed IC50 of 27.76 
± 0.14, 4.25 ± 0.07 and 12.05 ± 0.09 µg/mL against neuraminidase from Clostridium 
xxi 
 
perfringens, H1N1 and H5N1. Methanol and alkaloid extracts, fractions and the 
isolated compound showed significant inhibitory effect (p<0.05) compared with 
positive control in neuraminidase inhibition assay against all three types of 
neuraminidase enzymes. Molecular docking study of voaphylline performed via 
AutoDock 4.2 software showed that voaphylline, ervayunine and DANA had low 
binding energy of -7.31, -5.52 and -6.29 kcal/mol, respectively with H1N1 
neuraminidase receptor (PDB code: 3TI6) with a number of predicted bonding 
interactions involved. In silico screening of compounds had demonstrated that 
prediction of plants containing chemical compound of interest for a particular disease 
could be achieved via computational method with validation of the predicted 
compound’s activity was subjected to experimental evaluation via in vitro assay. 
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CHAPTER ONE 
INTRODUCTION 
 
 
1.1 The Influenza Virus 
Influenza or commonly known as flu is one of the most common but significant 
human respiratory infection due to its high morbidity and mortality rate. Influenza 
viruses may cause epidemics (seasonal infections) and pandemics (periodic and 
unpredictable infections) which lead to high number of infection and fatality 
(Taubenberger & Morens 2008). Younger and older generations with existing and 
chronic kidney failure, heart disease and respiratory problems as well as pregnant 
women are at higher risk for influenza infection (Douglas 1990; Woo 2010).  
 
One or more symptoms are usually shown by people that have been infected by 
influenza virus. Among the most common symptoms includes sneezing or dry 
coughing, sudden high fever, headache, sore throat, body weakness and muscle pains 
(Taubenberger & Morens 2008; Woo 2010). Besides that, influenza infection could 
also be accompanied by other symptoms such as diarrhoea, poor or loss of appetite 
and photophobia (Laver & Garman 2002; Naffakh & Werf 2009).  Severe influenza 
illness may cause other complication such as pneumonia (Gong et al. 2007).  
 
Pneumonia is the most common complication that occur following influenza 
infection. The complication might occur due to either secondary bacterial pneumonia 
or primary viral pneumonia (Gong et al. 2007). Pneumonia complication could also 
occur due to both primary viral pneumonia and secondary bacterial pneumonia 
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(Douglas 1990). Besides that, other less frequent complications were also reported 
due to post-influenza virus infection such as secondary bacterial infection, instable or 
abnormal cardiac electrocardiogram (ECG) readings due to inflammation of heart 
muscle and brain inflammation which could lead to brain damage or disease (Gong et 
al. 2007).  
 
There are three types of influenza virus; A, B and C which differ in the host range 
and ability in causing diseases. Influenza B and C are almost exclusively found in 
humans while Influenza A could be found in wider variety of mammals including 
birds, humans, pigs, horses and many other warm blooded animals (Suzuki 2005; 
Gong et al. 2007; Taubenberger & Morens 2008).  Wild waterfowls were reported to 
be the source of all known influenza virus subtypes while pigs which usually have 
close contact with humans and birds serve as the intermediate host for mixing of 
genetic materials from both human and avian influenza viruses due to its capacity to 
be infected by Influenza A viruses from both species (Brown 2000; Laver & Garman 
2002; Brown 2003). 
 
Influenza virus was firstly isolated from bird species followed by the isolation of 
swine influenza virus in 1931 and human influenza virus in 1933. However, the 
identification of the first influenza virus isolated was only done in the year 1955. 
Another human influenza virus was isolated in 1940. However, this newly isolated 
influenza virus was genetically different from the human influenza virus isolated in 
1933 (Gong et al. 2007).  
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It was reported that influenza viruses have unstable genetics which could lead to 
evolution of new viruses via either gene reassortment (antigenic shift) or point 
mutation (antigenic drift) (Taubenberger & Morens 2008). Influenza A which is the 
most virulent compared with the other two types of viruses, was reported to be the 
cause of epidemics and pandemics that occurred worldwide. Pandemics happened 
due to evolution of entirely new Influenza A virus subtypes via reassortment of its 
genome (antigenic shift) while epidemics occurred due to the changes of Influenza A 
and Influenza B surface antigens (Suzuki 2005; Gong et al. 2007; Bové et al. 2008). 
There are a number of influenza pandemic occurrences reported worldwide. 
However, the three influenza pandemics which occurred in 1918 (Spanish Influenza), 
1957 (Asian Influenza) and 1968 (Hong Kong Influenza) had left significant impact 
due to the high number of deaths. Spanish Influenza (1918) had recorded a total of 
50 million deaths worldwide while Asian Influenza (1957) and Hong Kong Influenza 
(1968) had caused 2 million and 1 million deaths, respectively (Oxford 2000). 
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1.2 Influenza Pandemic 
Influenza A (H1N1) virus was the most common cause of human flu in 2009 which 
had caused a global panic over H1N1 flu. Since late April 2009, the outbreak of 
influenza A (H1N1) virus has raised concerns of the risk of a global flu pandemic. 
Pandemic, according to Taubenberger & Morens (2008) is the emergence of a new 
infectious disease that causes serious illness and spreads easily among humans across 
globally.  
 
By June 11, 2009, nearly 30 000 of confirmed cases were reported by the World 
Health Organization (WHO) in more than 70 countries which led the organisation to 
raise the level of influenza pandemic alert to phase 6 which indicated that a global 
pandemic was underway (Halasa 2010; Woo 2010). Until the end of July 2010, more 
than 18 849 deaths from at least 214 countries with confirmed cases of influenza 
H1N1 were reported (WHO 2010a). After more than a year since the Influenza A 
H1N1 2009 pandemic, the number of reported cases have then slowed down and the 
world has moved from phase 6 of influenza A H1N1 pandemic to post-pandemic 
period (WHO 2010b). Although the Influenza A H1N1 2009 is already entering the 
post-pandemic period, it is expected that the virus will come back in future, 
considering the numbers and trend of pandemics that have occurred in the previous 
century. 
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The worst influenza A H1N1 pandemic recorded was in 1918 where approximately 
50 million people are killed worldwide due to the virus infection (Halasa 2010). All 
influenza A pandemics that occur since 1918 were reported to have been originated 
from the 1918 virus strain. This includes the H1N1 viruses that had been isolated 
after the 1918 influenza pandemic and reassorted H2N2 as well as H3N2 viruses as 
reported by Kilbourne (2006). It was reported that H2N2 and H3N2 viruses consists 
of key genes from 1918 virus that were incorporated with avian influenza genes. 
According to Krause (2006) and Taubenberger & Morens (2006), other recent 
pandemics have also shown to be linked with the 1918 virus thus, making the 1918 
influenza virus the mother of all pandemics. Therefore, intense studies and 
understanding of the genetics of the 1918 virus will certainly helpful in guiding the 
strategy to confront future influenza pandemics. 
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1.3 Influenza A Virus Structure 
Influenza A viruses are a group of viruses from Mononegavirales order and 
Orthomyxoviridae family (Tambunan et al. 2012). The virus structure could be either 
in the form of round bodies (spherical or ovoid) or long filaments containing 
enveloped negative-sense, single-stranded and segmented RNA genome (Gong et al. 
2007). Influenza A viruses are further subtyped according to the reactivity of their 
surface glycoproteins, namely haemagglutinin (HA) and neuraminidase (NA) (Qin et 
al. 2010; Woo 2010). These glycoproteins which cover the surface of the influenza 
virus play an important role in an influenza virus activity. Influenza A virus structure 
is illustrated in Figure 1.1. 
 
 
 
Figure 1.1: Influenza A virus structure (Davidson 2005) 
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1.4 Haemagglutinin (HA) 
HA which consists of sixteen subtypes (H1-H16) is a triangular rod-shaped molecule 
made up from three identical HA polypeptides embedded in the lipid membrane of 
influenza virus (Itzstein 2007). It is responsible for the binding of virus to the sialic 
acid (SA) receptor of the infected cells and to facilitate the fusion of the viral 
envelope with the host cell at the point of infection (Wiley & Skehel 1987; Russell et 
al. 2006). HA‟s binding sites are different between humans and birds. According to 
Oxford (2000) and Taubenberger & Morens (2006), influenza viruses in birds bind to 
the α(2,3) linked sugars while influenza viruses in humans bind to the α(2,6) linkages 
of sialic acid receptors of the host cell. The removal of sialic acid molecules from the 
host cell was proven not being able to stop infection from influenza virus (Gong et 
al. 2007). This suggests the existence of different receptor on the host cell which 
plays more important role in viral infection.  
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1.5 Neuraminidase Enzyme (NA) 
NA is a major surface glycoprotein on a virus structure. It has been identified by 
Alfred Gottschalk as neuraminidase or sialidase (Gong et al. 2007) with its 3-D 
structure was discovered in 1983 (Kubinyi 1998). It is a tetramer protein which is 
made from four identical polypeptides embedded in the viral membrane of influenza 
virus and consists of 9 subtypes, N1-N9 (Itzstein 2007). Each polypeptide is 
composed of six 4-stranded anti-parallel β-sheets. Studies have shown that NA, 
which consists of nine identical subtypes (N1-N9) plays important role in the 
replication, maturity and release or delivery of influenza virus (Russell et al. 2006).  
 
NA enzyme subtypes were divided into two distinct groups; group-1 neuraminidase 
and group-2 neuraminidase. Group-1 consists of N1, N4, N5 and N8 neuraminidase 
subtypes while group-2 consists of N2, N3, N6, N7 and N9 subtypes (Zhang et al. 
2008; Guo et al. 2010). Group-1 neuraminidases are able to bind to neuraminidase 
inhibitor, oseltamivir in either „open‟ or „closed‟ 150-loop conformation. However, 
group-2 neuraminidases are only able to bind to neuraminidase inhibitor in „closed‟ 
conformation. The „open‟ and „closed‟ 150-loop conformations help neuraminidase 
substrates to fit into the active site upon binding of ligands or inhibitors (Cheng et al. 
2008; Vries et al. 2012). 
 
Neuraminidase is an enzyme that facilitates movement of virus to and from the site 
of infection by catalysing the cleavages of (2,6)- or (2,3)-ketosidic linkage that exists 
between a terminal sialic acid and an adjacent sugar residue. The catalysing of 
cleavages are important in facilitating the movement of viruses, to prevent           
self-aggregation of viruses after being released from host cells, to prevent 
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inactivation of viruses and also to promote penetration of viruses into respiratory 
epithelial cells (Russell et al. 2006). Besides that, important role of NA influenza 
virus and Streptococcus pneumonia has also led to the secondary bacterial 
complication which was the main reason for influenza-associated death (Gong et al. 
2007).  
 
Both HA and NA recognise the same host cell molecule, SA or also known as         
N-acetylneuraminic acid (Neu5Ac) receptor. The functional balances between these 
two glycoproteins are important in virus replication (Wagner et al. 2002; Gong et al. 
2007). As discussed by Gong et al. (2007), Itzstein (2007) and Taubenberger & 
Morens (2008), HA plays important role by facilitating the attachment of virus to the 
host cells. However, without NA, the virus cannot enter the cells as the cleavage of 
SA could not occur hence; the spread of the virus to other cells may be suppressed. 
Due to this reason, NA has been recognised as the main target for the design of     
anti-influenza agents. An intensive study and understanding of neuraminidase 
structure would be very useful in designing and synthesising neuraminidase 
inhibitors. 
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1.6 Neuraminidase Active Sites 
Neuraminidase active sites consist of highly conserved amino acid residues, mainly 
of aspartic acid (Asp), glutamic acid (Glu) and arginine (Arg) amino acid residues. 
The active sites are divided into 5 main regions, namely Site 1 (S1), Site 2 (S2), Site 
3 (S3), Site 4 (S4) and Site 5 (S5). S1 region is made up of Arg 118, Arg 292 and 
Arg 371 residues that bind to carboxylate group of inhibitor. S1 region provides 
suitable condition for binding of anionic substituents from inhibitors due to its 
positively charged and hydrogen-bonding environments. S2 region, which consists of 
Glu 119, Glu 227 and Asp 151 residues, on the other hand is a negatively charged 
region active site, which interacts with guanidino group of inhibitors. S3 region, 
which is a small hydrophobic region, consists of Ile 222 and Trp 178 that are 
adjacent to Arg 152 side chain. S4 on the other hand is the main hydrophobic region 
made of Ile 222, Ala 246 and Arg 224 amino acid residues. S5 region, which consists 
of the carboxylate group of Glu 276 and methyl group of Ala 246 is a region of 
mixed polarity (Stoll et al. 2003). Figure 1.2 illustrates neuraminidase binding sites 
with 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (Neu5Ac2en) inhibitor. 
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Figure 1.2: Illustration of five neuraminidase active sites (S1-S5) with Neu5Ac2en 
inhibitor (Stoll et al. 2003) 
 
 
According to Lew et al. (2000), neuraminidase binding sites could also be divided 
into three major binding pockets: Pocket 1 (P1), Pocket 2 (P2) and Pocket 3 (P3). P1 
consists of highly polar residues of Glu 276, Glu 277, Arg 292, Asn 294 and 
hydrophobic residue of Ala 246 which form interaction with glycerol moiety of SA. 
However, a study conducted had discovered that there was also high binding affinity 
by cyclohexene based neuraminidase inhibitors due to nonpolar interactions with 
amino acid residues in P1. P2 are made up by highly conserved amino acid residues 
which are Ile 222, Arg 224 and Ala 246. These amino acid residues are not involved 
in binding of SA but favourable hydrophobic interactions were reported to be made 
by the cyclohexene of neuraminidase inhibitors. P3 on the other hand is a large 
neuraminidase binding pocket which consists of hydrophobic and hydrophilic 
residues. This binding pocket is surrounded by Glu 119, Asp 151, Arg 152, Trp 178, 
Ser 179, Ile 222 and Glu 227 amino acid residues. Important amino acid residues 
with important binding pockets are shown in Figure 1.3. It is crucial to identify the 
binding pocket prior conducting docking study. Alternatively, original crystal 
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structure containing inhibitor or ligand could be used in identifying important 
binding sites. 
 
 
Figure 1.3: Illustration of oseltamivir bounds to the wild type strain of 2009-H1N1 
influenza neuraminidase. This modelled structure was adapted and modified from 
Rungrotmongkol et al. (2010). 
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1.7 Neuraminidase Inhibitor and The Development of Antivirals 
Neuraminidase enzyme plays critical roles in the life of influenza virus. This includes 
facilitating the release of the virus to other neighbouring cells by cleaving SAs from 
cellular receptor thus; NA has been identified as the target to develop therapeutic 
strategies against the viral infection. Based on the understanding of the enzyme‟s 
structure and functions, medicinal chemists have been designing and synthesising 
neuraminidase inhibitor (NAI) in order to overcome viral infection (Gong et al. 
2007). Neuraminidase inhibitors mimic the natural substrate and bind to the active 
site, thus prevent the virus from reproducing and infecting other neighbouring host 
cells (Russell et al. 2006). Illustration of NA enzyme function in viral infection could 
be seen in Figure 1.4.  
 
 
Figure 1.4: Mechanism of action of neuraminidase inhibitors.  
A: Replication and release of virus to new host cells continues as neuraminidase 
enzyme cleaves the receptor containing sialic acid that binds with haemagglutinin  
B: Viral replication discontinued as neuraminidase inhibitor binds to the active site 
(Moscona 2005) 
 
 
14 
 
1.7.1 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (Neu5Ac2en/DANA)  and  
         2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA) 
The first neuraminidase enzyme inhibitors discovered were dehydrated and 
fluorinated sialic acid, DANA and FANA (Figure 1.5). These two inhibitors, which 
were discovered by Peter Palese and his colleagues in 1970, are very effective 
against influenza neuraminidase. Unfortunately, these two inhibitors are found to be 
and only effective in cell culture (in vitro). Therefore, the search for neuraminidase 
inhibitor which could inhibit neuraminidase activity in vivo are intensified (Laver & 
Garman 2002). 
 
 
 
Figure 1.5: Molecular structures of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid 
(DANA) and 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA) 
(Clercq 2006) 
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1.7.2 Adamantane Derivatives 
Several anti-influenza drugs or vaccines have been designed to combat influenza 
viruses based on intensive study on the structure of influenza virus. The first two 
drugs available to treat influenza in human and infected animals were adamantane 
derivatives; rimantadine and amantadine (Gong et al. 2007; Itzstein 2007). The 
derivatives were firstly found in petroleum in 1933 by Landa and Machacek. Eight 
years later (1941), Prelog and Seiwerth have successfully synthesised adamantane 
derivatives for the first time (Guo et al. 2010). These two drugs (Figure 1.6) act by 
interfering with the M2 protein ion channel function that is only found in influenza A 
virus (Laver & Garman 2002; Taubenberger & Morens 2008).  
 
 
 
Figure 1.6: Molecular structures of M2 channel inhibitors; rimantadine (left) and 
amantadine (right)  (Liu et al. 2010) 
 
M2 protein plays important role during viral replication as it equilibrates pH of the 
viral membrane during viral maturation (Qin et al. 2010). The blocking of M2 ion 
channel activity will inhibit the uncoating of influenza viruses in the infected cells 
hence, will prevent the replication of the virus‟ RNA (Suzuki 2005). However, these 
two drugs have been reported to cause side effects on the central nervous system 
[CNS] (Itzstein, 2007). Adamantane derivatives were also reported to be effective 
against influenza A viruses only. Besides that, the derivatives have also caused 
nausea, dizziness, depression, hallucinations and anxiety in patients undergone 
treatment (Bové et al. 2008). Rapid emergence of drug resistance from the use of 
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these two drugs has also been reported (Laver & Garman 2002). During H1N1 
influenza pandemic in 2009, 99.8% of patients in the US were reported to be 
resistance against both rimantadine and amantadine (Woo 2010).  
 
 
1.7.3 Oseltamivir and Zanamivir 
Two newer antiviral class of neuraminidase inhibitors available in the market are 
zanamivir (Relenza) and oseltamivir (Tamiflu). Structures of these two drugs are 
shown in Figure 1.7. Zanamivir and oseltamivir are effective against both influenza 
A and B viruses by interfering with the release of the virus from the infected cells 
(Suzuki 2005; Taubenberger & Morens 2008).  
 
Zanamivir or commercially known as Relenza by GlaxoSmithKline (GSK) was 
approved as anti-influenza drug in 1999 and is marketed as inhaled anti-influenza 
drug which could directly deliver the drug to the site of infection (Itzstein 2007; 
Grienke et al. 2010). According to Itzstein (2007), the drug is marketed as inhaled 
formulation due to its limited bioavailability as the drug has high polarity in nature 
and the compound is rapidly excreted from the body.  
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Figure 1.7: Molecular structures of neuraminidase inhibitors; zanamivir and 
oseltamivir (Liu et al. 2010) 
 
 
Oseltamivir on the other hand is the first orally active sialidase inhibitor that has 
been approved for treating influenza (Itzstein 2007). The drug which is commercially 
known as Tamiflu is marketed by Gilead/Roche. However, rapid emergence of drug-
resistance has been reported against the use of oseltamivir as anti-influenza drug. 
Russell et al. (2006) reported that mutations had occurred at the active sites of 
neuraminidase enzyme which led to inhibitor resistance.  Since neuraminidase 
continues to be attractive for the development of new virus inhibitors, the search for 
novel neuraminidase inhibitors against influenza virus still remains as a worldwide 
priority.  
 
 
 
 
 
 
 
 
18 
 
1.8 Anti-Influenza from Natural Product 
Currently, a number of studies on natural products have been conducted by other 
researchers to isolate chemical compounds with potential antiviral activities. For 
instance, an experimental study of propolis (bee glue) was conducted to investigate 
the potential use of propolis extract as antiviral. From this study, diethyl ether 
fraction of propolis extract showed inhibitory effect on the activity of H1N1 and 
H3N2 viruses (Serkedjieva et al. 1992).  On the other hand, an in vitro study 
conducted by Watanabe et al. (2014) showed that manuka honey has high activity in 
inhibiting influenza virus replication in MDCK cells.  
 
Inhibition of human inﬂuenza A/Hong Kong (H3N2) replication in MDCK was also 
reported by Haidari et al. (2009) in their study on polyphenol extract of pomegranate 
or scientifically known as Punica granatum. Another study conducted by another 
research group on the potential use of plant-derived isoquercetin as influenza virus 
inhibitor showed that the compound was capable of inhibiting the replication of 
influenza A and B viruses (Kim et al. 2010). Besides that, reduction of viral 
replication (in vitro) was also reported in a study of double treatment of isoquercetin 
and amantadine. Study on water extracts of five traditional Chinese medicines which 
are Duchesnea indica Andr., Liquidambar formosana Hance., Lithospermum 
Erythrorhizon Sieb. et Zucc., Melia toosendan Sieb. et Zucc. and Prunella vulgaris 
L. had also showed reduction of virus yield in MDCK cells as reported by Tian et al. 
(2011). 
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Experimental study on water extract of Psidium guajava Linn. (guava) tea conducted 
by Sriwilaijaroen et al. (2012) on the other hand showed growth inhibition of H1N1 
influenza virus isolated from the 2009 pandemic strain. Similarly, β-santalol 
compound isolated from hexane extract of dried sandalwood (Santalum album L.) 
showed high antiviral activity with 86% inhibition at 100 µg/mL concentration 
against influenza A H3N2 virus in MDCK cells (Paulpandi et al. 2012). Studies on 
methanolic extract of Saudi plants (Adenium obesum and Tephrosia nubica) and 
ethanolic extract of Peperomia sui Lin and Lu, an endemic species of plant in 
Taiwan conducted by Kiyohara et al. (2012) and Yang et al. (2014), respectively 
have also reported inhibition of antiviral activity in cells. 
 
The local plant selected in this project was identified by in silico screening from 
Natural Product Discovery (NADI) system conducted by the other member of our 
group. The pharmacological properties of the natural compound from the best 
docking results were evaluated via enzyme assay (neuraminidase inhibition assay).  
From the neuraminidase inhibition assay, methanol extract of Tabernaemontana 
divaricata leaves gave one of the highest percentages of neuraminidase inhibition 
thus, this plant was selected for extraction, isolation and elucidation of its chemical 
constituent with potential anti-neuraminidase activity.  
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1.8.1 Tabernaemontana divaricata (L.) R.Br. ex Roem. & Schult.  
Kingdom : Plantae (Plants) 
Subkingdom : Tracheobionta (Vascular plants) 
Superdivision : Spermatophyta (Seed plants) 
Division : Magnoliophyta (Flowering plants) 
Class : Magnoliopsida (Dicotyledons) 
Subclass : Asteridae 
Order : Gentianales 
Family : Apocynaceae 
Genus : Tabernaemontana (L.) 
Species : Tabernaemontana divaricata (L.) 
 
Source taken from USDA, NRCS (2011) website, retrieved 20
th
 August 2011. 
 
Pictures of T. divaricata plant and list of the plant‟s synonyms are shown in Figure 
1.8 and Table 1.1, respectively. 
 
           
 
Figure 1.8: Pictures of Tabernaemontana divaricata plant, taken from sampling site 
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Table 1.1: Synonyms of Tabernaemontana divaricata (L.) R.Br. ex Roem. & Schult. 
obtained from The Plant List website (2013) 
 
Species Synonyms 
Tabernaemontana 
divaricata (L.)  
R.Br. ex Roem. & 
Schult. 
Ervatamia coronaria (Jacq.) Stapf 
Ervatamia divaricata (L.) Burkill 
Ervatamia divaricata var. plena (Roxb. ex Voigt) M.R.Almeida 
Ervatamia flabelliformis Tsiang 
Ervatamia recurva (Roxb. ex Lindl.) Lace 
Ervatamia siamensis (Warb. ex Pit.) Kerr 
Jasminum zeylanicum Burm.f. 
Kopsia cochinchinensis Kuntze 
Nerium coronarium Jacq. 
Nerium divaricatum L. 
Nyctanthes acuminata Burm.f. 
Reichardia grandiflora Dennst. 
Reichardia jasminoides Dennst. 
Taberna discolor (Sw.) Miers 
Tabernaemontana citrifolia Lunan 
Tabernaemontana coronaria (Jacq.) Willd. 
Tabernaemontana coronaria var. plena Roxb. ex Voigt 
Tabernaemontana discolor Sw. 
Tabernaemontana flabelliformis (Tsiang) P.T.Li 
Tabernaemontana gratissima Lindl. 
Tabernaemontana indica Willd. ex Roem. & Schult. 
Tabernaemontana lurida Van Heurck & Müll.Arg. 
Tabernaemontana recurva Roxb. ex Lindl. 
Tabernaemontana recurva Roxb. 
Tabernaemontana siamensis Warb. ex Pit. 
Testudipes recurva (Roxb. ex Lindl.) Markgr. 
Vinca alba Noronha 
 
T. divaricata is one of more than 100 species of flowering plants that belongs to the 
family of Apocynaceae.  The plant is also known as Crepe Jasmine, Pinwheel flower, 
Coffee rose and Spiral gardenia. Locally, T. divaricata plant is known as “pokok 
akar susun kelapa” and “pokok bunga cina”. The plant is a multi-branched evergreen 
shrub which could reach up to 6-feet high. Its thick, dark green leaves are arranged 
opposite or sub-opposite on the stem and are fairly large. The 5 petal white flowers 
have sweet scent and are arranged in groups from the stems growing point. There is 
also another variety of flower called “Flore Pleno” which is a double petal variety 
and has more ruffled wavy petals (Pratchayasakul et al. 2008).    
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The uses of plants for medicinal purposes are very important since the ancient times 
due to the limited alternative therapy available for treatment of various diseases. 
Chinese, Indian and Thai folks have widely used Tabernaemontana plants for a 
number of treatments including fever, pain and dysentery which is an inflammatory 
disorder in the intestines due to infection (Henriques et al. 1996; Rumzhum et al. 
2012). The genus could be found abundance is many tropical countries such as 
Brazil, Egypt, India, Sri Lanka, Malaysia, Vietnam and Thailand.  
 
 
1.8.2 Traditional Use of Tabernaemontana divaricata Plant Parts 
The plant extract was found to possess analgesic and CNS depressant effects, 
cytotoxic activity and is also found to be useful in the treatment of cancer during the 
ancient times (Hsu 1967). In addition to that, various parts of this plant are 
traditionally used in India for a number of treatments. The plant material is widely 
used to treat diarrhoea, as a purgative and tonic, especially to the brain, liver and 
spleen. The roots of the plant are chewed to relieve tooth-ache while the plant‟s latex 
on the other hand has a cooling effect and could be applied to wounds to prevent 
inflammation. The latex could also be mixed with oil and applied to head to relieve 
headaches, eye pressure and corneal inflammation (Kirtikar & Basu 1987).  
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1.8.3 Recent Study on Tabernaemontana divaricata Plant 
In vitro and in vivo study on methanol extract of T. divaricata leaves showed 
potential anti-acetylcholinesterase activity to treat Alzheimer disease.  
Acetylcholinesterase is the main enzyme in nervous system that affects 
neurotransmission which results in memory and behaviour impairment in people 
with Alzheimer disease (Ingkaninan et al. 2003; Chattipakorn et al. 2007). Besides 
that, methanol extract of T. coronaria (syn: T. divaricata) leaves had also showed 
high anti-tuberculosis activity against Mycobacterium tuberculosis strain with 
minimum inhibitory concentration (MIC) reported to be 800 µg/mL (Mohamad et al. 
2011). In addition, experimental studies on five different type (ethanol, petroleum 
ether, diethyl ether, methanol and aqueous) of extracts obtained from T. divaricata 
leaves proved the effectiveness of these extracts against a number of infectious 
pathogens including Staphylococcus saprophyticus, Staphylococcus aureus, 
Staphylococcus pyogenes, Enterococus facealis, Streptococcus agalactae, 
Salmonella typhi, Escherichia coli, Shigella boydii, Shigella dysenteriae and 
Pseudomonas aeruginosa (Ashikur et al. 2011). 
 
Furthermore, antidiabetic activity of methanol extract obtained from T. divaricata 
leaves was also reported by Masudur Rahman et al. (2012). In this study, methanol 
extract of T. divaricata leaves showed its effectiveness in lowering blood sugar level 
in diabetic mice model. Methanol and aqueous flower extract of T. divaricata on the 
other hand showed anti-fertility effect in rats. Study conducted by Mukhram et al. 
(2012) showed that methanol flower extract of T. divaricata could lead to early 
abortion due to its anti-implantation activity while both methanol and aqueous flower 
extracts of T. divaricata showed significant estrogenic activity at 500 mg
.
kg
-1
. 
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Study on anti-diarrhoeal for T. divaricata leaves was reported for the first time in 
2013. Hydroalcoholic and aqueous extract of the plant leaves showed significant 
activity in rats hence; validating the traditional use of this plant part in treating 
diarrhoea (Raj et al. 2013).  On the other hand, Jain et al. (2013) had proved the use 
of T. divaricata leaves as anti-inflammation agent in India. Experimental study 
showed that hexane fraction obtained from T. divaricata leaves showed high 
inhibition (42.1% inhibition at 0.7 µg
.
cm
-2
) on male albino mice. 
 
1.8.4 Alkaloid Chemical Constituents from Tabernaemontana  divaricata 
The phytochemistry of T. divaricata has been extensively studied due to its wide 
range of medicinally important application. Chemical constituents isolated from 
various part of this plant were classified as alkaloids, sterols, triterpenoids, steroids, 
flavonoids, phenyl propanoids, phenolic acids and enzymes (Gupta et al. 2004; 
Pratchayasakul et al. 2008). Generally, the classification of chemical constituents 
from plants was done according to their biosynthetic origin, solubility properties and 
the presence of certain key functional groups in the isolated compounds. 
 
Based on the in silico screening from NADI database conducted by the other group 
of this project, compound(s) of interest to be isolated from this plant are classified as 
alkaloids. Alkaloids are the largest secondary plant metabolites with over 27,000 
compounds have been successfully isolated and identified for various studies 
(Amirkia & Heinrich 2014). It has basic chemical property due to the presence of at 
least one nitrogen atom in each compound. 
 
